These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 7490996)
1. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Haq IU; Jackson PR; Yeo WW; Ramsay LE Lancet; 1995 Dec; 346(8988):1467-71. PubMed ID: 7490996 [TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering for prevention of coronary heart disease: what policy now? Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865 [TBL] [Abstract][Full Text] [Related]
3. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. Megnien JL; Levenson J; Simon A Lancet; 1996 Feb; 347(8999):468; author reply 468-9. PubMed ID: 8618501 [No Abstract] [Full Text] [Related]
4. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients? Deedwania PC Geriatrics; 2000 May; 55(5):22-8. PubMed ID: 10826262 [TBL] [Abstract][Full Text] [Related]
6. [Statins in primary prevention of coronary heart disease]. Paulweber B Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004 [TBL] [Abstract][Full Text] [Related]
8. Cholesterol reduction to prevent CAD. What do the data show? Sorrentino MJ Postgrad Med; 2000 Dec; 108(7):40-2, 45-6, 49-52. PubMed ID: 11126142 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Martens LL; Guibert R Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684 [TBL] [Abstract][Full Text] [Related]
10. Prevention of coronary heart disease through cholesterol reduction. Grundy SM Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652 [TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the new Sheffield table and the modified joint British societies coronary risk prediction chart against a laboratory based risk score calculation. Rabindranath KS; Anderson NR; Gama R; Holland MR Postgrad Med J; 2002 May; 78(919):269-72. PubMed ID: 12151567 [TBL] [Abstract][Full Text] [Related]
12. Cholesterol management in the era of managed care. Grundy SM Am J Cardiol; 2000 Feb; 85(3A):3A-9A. PubMed ID: 10695701 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787 [TBL] [Abstract][Full Text] [Related]
14. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO]. Simoons ML; Casparie AF Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223 [TBL] [Abstract][Full Text] [Related]
15. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930 [TBL] [Abstract][Full Text] [Related]
17. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067 [TBL] [Abstract][Full Text] [Related]
18. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH; Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833 [TBL] [Abstract][Full Text] [Related]
19. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. Goldman L; Weinstein MC; Goldman PA; Williams LW JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]